Raymond James Financial Comments on TSE:HLS Q2 Earnings

HLS Therapeutics Inc. (TSE:HLS) – Research analysts at Raymond James Financial upped their Q2 2026 earnings estimates for HLS Therapeutics in a report issued on Tuesday, November 18th. Raymond James Financial analyst M. Freeman now expects that the company will post earnings of ($0.07) per share for the quarter, up from their previous forecast of ($0.08). Raymond James Financial has a “Moderate Buy” rating and a $6.00 price objective on the stock. The consensus estimate for HLS Therapeutics’ current full-year earnings is ($0.12) per share. Raymond James Financial also issued estimates for HLS Therapeutics’ FY2026 earnings at ($0.31) EPS, FY2027 earnings at ($0.07) EPS, FY2028 earnings at $0.20 EPS and FY2029 earnings at $0.45 EPS.

HLS Therapeutics Stock Up 1.6%

Shares of TSE HLS opened at C$5.00 on Friday. The company has a debt-to-equity ratio of 86.50, a current ratio of 1.56 and a quick ratio of 1.01. The company has a market cap of C$156.37 million, a P/E ratio of -11.11 and a beta of 0.44. HLS Therapeutics has a 1 year low of C$3.20 and a 1 year high of C$5.77. The firm has a 50-day simple moving average of C$5.45 and a two-hundred day simple moving average of C$5.16.

HLS Therapeutics (TSE:HLS) last released its earnings results on Thursday, November 13th. The company reported C($0.12) earnings per share (EPS) for the quarter. HLS Therapeutics had a negative return on equity of 25.27% and a negative net margin of 38.70%.The firm had revenue of C$18.81 million during the quarter.

About HLS Therapeutics

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris.